Market Place
Sourcing Support
Chiesi Reports Phase 3 Results of ELFABRIO® in Fabry Disease
28 Oct 2024 //
PR NEWSWIRE
Chiesi Announces New Research Grant Initiative
09 Sep 2024 //
CONTRACT PHARMA
Chiesi Showcases Rare Disease Commitment At ENDO 2024 Debut
14 Jun 2024 //
GLOBENEWSWIRE
Chiesi Presents At ENDO 2024 Endocrinology Meeting
22 May 2024 //
GLOBENEWSWIRE
Chiesi Global Rare Diseases Launches Rethink Acromegaly Campaign
01 Mar 2024 //
GLOBENEWSWIRE
PANTHERx® Rare Selected by Chiesi for the Distribution of Filsuvez topical gel
05 Feb 2024 //
PR NEWSWIRE
Chiesi Announces Health Canada Approval of MYALEPTA
05 Feb 2024 //
GLOBENEWSWIRE
Chiesi Announces Publication of Results from Phase 3 Study in Fabry Disease
10 Jan 2024 //
PR NEWSWIRE
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ topical gel
19 Dec 2023 //
GLOBENEWSWIRE
Chiesi Global Announces Multiple Presentations at SSIEM Annual Symposium 2023
01 Sep 2023 //
PR NEWSWIRE
Chiesi Global Rare Diseases and Protalix Announce FDA Approval of ELFABRIO®
10 May 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.